首页> 外文会议>International Conference on Chemical Engineering and Advanced Materials >Preparation of a novel complex antimicrobial agent and its antimicrobial activity in vitro
【24h】

Preparation of a novel complex antimicrobial agent and its antimicrobial activity in vitro

机译:一种新型复合抗微生物剂及其体外抗微生物活性的制备

获取原文

摘要

Purpose To develop a novel complex antimicrobial agent and determine the optimal components of the composite antimicrobial agents and its antimicrobial activity in vitro. Methods According to antimicrobial mechanisms, antibacterial spectrums, physical and chemical properties and applicabilities of existing antimicrobial agents in clinical use, select out cefoperazone sodium, sulbactam sodium and cephradine as the basic components to make a novel complex antimicrobial agent. Utilize yeast, staphylococcus aureus and E. coli bacteria as test bacteria. Do the three factors four-level orthogonal experiments by the maximum amount, the middle amount, low amount and Minimum amount of the three-component agent to research the optimum ratio of the drug. Measure the titer of the compound antimicrobial agent by the way of tube-plate method (2 doses). With known contents of Penicillin Sodium for Injection as control, and determine its minimum inhibitory concentration against staphylococcus aureus, E. coli and yeast by using the agar doubling dilution method. The experimental results were analysized by statistical analysis software SPSS16.0. Results The results of the three factors four-level orthogonal experiments indicate the optimum ratios of Cefoperazone Sodium, Sulbactam Sodium and Cephradine against E. coli, yeast and staphylococcus aureus were 2:2:3, 1:2:2 and 2:6:5, their titers were 1353.9U/mg, 982.7U/mg and 1015.5U/mg. With the highest titer proportion 2:2:3 as the composition of the antimicrobial compound. This compound antimicrobial agent had a good antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria and Fungi, its minimal inhibitory concentration (MIC) against staphylococcus aureus, E. coli and yeast were 2.000μg/ml, 0.500μg/ml and 16.000μg/ml. Conclusion This research acquires a composite of antibiotics. This antimicrobial compound has a broader spectrum and higher antimicrobial activity in vitro comparing with traditional common single antibiotics, and it especially has a good antimicrobial activity against fungi. The results set a scientific foundation for enriching clinical medicines.
机译:目的开发一种新型复合抗微生物剂,并在体外测定复合抗微生物剂的最佳组分及其抗微生物活性。方法根据抗微生物机制,抗菌谱,身份抗菌剂的物理和化学性质以及临床用途的应用,选择大群体钠,舒巴酰胺钠和卡氨酸作为制作新型复合抗微生物剂的碱性组分。利用酵母,金黄色葡萄球菌和大肠杆菌细菌作为测试细菌。通过最大量,三级正交实验进行三个因素,三组分代理的中等量,少量和最小量,以研究药物的最佳比例。通过管板方法(2剂量)测量复合抗微生物剂的滴度。用已知的青霉素钠作为对照注射的含量,并通过使用琼脂倍增稀释方法来确定其对金黄色葡萄球菌的最小抑制浓度,例如Coli和酵母。通过统计分析软件SPSS16.0分析实验结果。结果三级正交实验的结果表明,对大肠杆菌,酵母和金黄色葡萄球菌的头孢唑酮钠,苏氨酰胺钠和卡萘啶的最佳比率为2:2:3,1:2:2和2:6: 5,它们的滴度为1353.9u / mg,982.7u / mg和1015.5u / mg。滴度比例最高2:2:3作为抗微生物化合物的组成。该复合抗菌剂对革兰氏阳性细菌,革兰氏阴性细菌和真菌具有良好的抗微生物活性,其对金黄色葡萄球菌的最小抑制浓度(MIC),大肠杆菌和酵母为2.000μg/ ml,0.500μg/ ml和16.000 μg/ ml。结论本研究获得了抗生素的复合材料。该抗微生物化合物具有更广泛的谱和更高的抗微生物活性,与传统的常见单抗生素相比,特别是对真菌的良好抗菌活性。结果为富集临床药物制定了科学的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号